943654-22-6

Basic information

• Product Name: 3-methyl-4-(2,2,2-trifluoro-acetylamino)-benzenesulfonyl chloride
• Synonyms: 3-methyl-4-(2,2,2-trifluoro-acetylamino)-benzenesulfonyl chloride
• CAS NO: 943654-22-6
• Molecular Weight: 301.674
• Mol File: 943654-22-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 3-methyl-4-(2,2,2-trifluoro-acetylamino)-benzenesulfonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-methyl-4-(2,2,2-trifluoro-acetylamino)-benzenesulfonyl chloride(943654-22-6)
• EPA Substance Registry System: 3-methyl-4-(2,2,2-trifluoro-acetylamino)-benzenesulfonyl chloride(943654-22-6)

Safety Data

• Hazardous Substances Data: 943654-22-6(Hazardous Substances Data)

Upstream product

• 95-53-4 o-toluidine 
• 2727-68-6 2,2,2-trifluoro-N-o-tolylacetamide 

Downstream Products

• 1349807-53-9 4-amino-N-(2-methyl-4-((4S)-5-methyl-2-oxo-4-phenylimidazolidin-1-ylsulfonyl)phenyl)benzamide 
• 1349807-51-7 N-(2-methyl-4-((4S)-5-methyl-2-oxo-4-phenylimidazolidin-1-ylsulfonyl)phenyl)-4-nitrobenzamide 
• 1349807-48-2 ethyl 2-methyl-4-((4S)-5-methyl-2-oxo-4-phenylimidazolidin-1-ylsulfonyl)phenylcarbamate 
• 1349808-14-5 1-(4-amino-3-methylphenylsulfonyl)-5-methyl-4-phenylimidazolidin-2-one 
• 1349808-11-2 4-(2-methoxy-5-methyl-4-phenyl-4,5-dihydroimidazol-1-ylsulfonyl)-2-methylbenzenamine 
• 1187966-58-0 N-(4-{[(2,3-diaza-spiro[4.4]non-3-en-2-yl)-ethylamino-methylene]-sulfamoyl}-2-methyl-phenyl)-2,2,2-trifluoro-acetamide 
• 823786-84-1 (S)-1-(4-Amino-3-methyl-benzenesulfonyl)-4-phenyl-imidazolidin-2-one 
• 445415-21-4 2,2,2-trifluoro-N-(2-methyl-4-sulfamoyl-phenyl)-acetamide 

Relevant articles and documents

ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS

This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5- HT6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, Irritable Bowel Syndrome, obesity and type-2 diabetes. The compounds have the general formula (1) wherein the symbols have the meanings given in the description.